NATCO Pharma rights issue is a verified India-business development with a defined immediate consequence. This report separates the public record from the outcomes that still need evidence, so readers can see what changed, why it matters and what should be measured next.
Our angle: Everyone else is repeating the headline amount; we are explaining the shareholder choice, arithmetic and dilution boundary.
What NATCO approved
NATCO Pharma’s board finalised a rights issue of up to ₹1,279.36 crore on 25 September 2026. The NATCO Pharma rights issue will offer 1,70,58,082 fully paid shares at ₹750 each, including a ₹748 premium over the ₹2 face value. Eligible shareholders receive two rights shares for every 21 fully paid shares held on the 1 October record date.
The offer is scheduled to open on 12 October and close on 22 October, with on-market renunciation planned through 16 October. Those dates turn an earlier fund-raising approval into a defined shareholder decision. They do not make the offer compulsory: entitlement holders can subscribe, renounce where permitted, or let an entitlement lapse.
The dilution arithmetic
If fully subscribed, NATCO’s outstanding shares would rise from 17,91,09,870 to 19,61,67,952. That is roughly a 9.5% increase over the pre-issue share count; the new shares would represent about 8.7% of the enlarged total. A shareholder who takes the full 2-for-21 entitlement broadly maintains proportional ownership, while one who does not participate can be diluted.
That calculation is about ownership percentage, not a prediction of market price. The economic outcome also depends on the value created by the capital, the issue discount at the relevant time and how the additional shares affect earnings per share.
What the proceeds are meant to do
Independent reporting based on the offer documents says up to ₹810.5 crore is intended for repayment or prepayment of borrowings and up to ₹110 crore for research and development. The balance can support inorganic opportunities and general corporate purposes within the disclosed limits. Debt repayment can reduce finance costs, but the actual benefit depends on timing, interest rates and the amount finally raised.
Readers should distinguish final issue terms from future deployment. The board has fixed price, ratio and dates; it has not yet demonstrated the savings, research output or acquisition returns that the new capital may produce.
What shareholders should watch
The immediate checkpoints are the letter of offer, rights-entitlement credit, renunciation window, subscription outcome and allotment. Investors with fewer than 21 shares may receive no fractional entitlement, although the filing provides a route to apply for additional shares subject to availability. Individual tax and trading consequences require personal advice.
The answer-first conclusion is that the NATCO Pharma rights issue gives existing owners a priced, time-bound choice. The 2-for-21 ratio limits the arithmetic ambiguity, but the long-term judgment is whether debt reduction, R&D and any inorganic use of funds earn more than the dilution they create.
NATCO Pharma rights issue facts
| Measure | Verified detail |
|---|---|
| Issue size | Up to ₹1,279.36 crore |
| Issue price | ₹750 per rights share |
| Entitlement | 2 shares for every 21 held |
| Record date | 1 October 2026 |
| Subscription window | 12–22 October 2026 |
Read our Ratnaveer rights allotment coverage. Read our Venus Pipes preferential issue coverage.
Frequently asked questions
What is the NATCO Pharma rights issue price?
The issue price is ₹750 for each fully paid rights equity share.
What is the entitlement ratio?
Eligible holders can apply for two rights shares for every 21 fully paid shares held on the record date.
When does the rights issue open?
The disclosed window is 12 October to 22 October 2026, with on-market renunciation ending 16 October.
Get the day’s top stories in your inbox
One concise email. No spam, unsubscribe anytime.
